Table IV.

Kaplan-Meier estimates of time-to-event outcomes.

	LPC
Time-to-event outcome	Non-high-risk	High-risk	LAPC	Overall
PSA progression-free survivala
n	361	208	106	675
Median (95% CI), months	n.a.	n.a.	n.a.	n.a.
1-year rate (95% CI), %	98.9	97.1	100.0	98.5 (97.6–99.4)
5-year rate (95% CI), %	87.4	78.7	79.9	82.9 (77.3–100.0)
Metastasis-free survivalb
n	366	233	110	709
Median (95% CI), months	n.a.	n.a.	n.a.	n.a.
1-year rate (95% CI), %	98.9	98.3	100.0	98.9 (98.1–99.7)
5-year rate (95% CI), %	91.8	78.5	91.7	87.5 (82.6–92.7)
Disease-free survivala
n	361	208	106	675
Median (95% CI), months	n.a.	n.a.	n.a.	n.a.
1-year rate (95% CI), %	99.2	98.1	100.0	98.9% (98.2–99.7)
5-year rate (95% CI), %	88.4	79.9	79.1	83.7 (78.0–89.8)
Progression-free survivalc
n	22	39	10	71
Median (95% CI), months	32.9 (27.1–46.0)	29.5 (24.4–44.5)	29.1 (26.3–41.8)	29.9 (26.5–41.0)
1-year rate (95% CI), %	90.5	86.5	100.0	89.7 (92.7–97.2)
5-year rate (95% CI), %	0.0	0.0	0.0	0.0
Overall survivald
n	433	244	113	790
Median (95% CI), months	n.a.	n.a.	n.a.	n.a.
1-year rate (95% CI), %	100.0	99.2	100.0	99.8 (99.4–100)
5-year rate (95% CI), %	96.8	88.8	87.9	92.9 (90.2–95.7)

^aIn patients treated with curative intent (n=675),

^bin patients treated with curative or palliative intent (n=709),

^cin patients treated with palliative intent (n=71),

^din all patients (n=790). LPC, localised prostate cancer; LAPC, locally advanced prostate cancer; CI, confidence interval; n.a., median not achieved.